• INmune Bio signed an amended and restated material transfer and license agreement with UK charity Anthony Nolan to expand collaboration around CORDStrom, its umbilical cord-derived mesenchymal stromal cell platform.
• Restated agreement took effect April 29, 2026, securing long-term supply of screened umbilical cord tissue to support development of off-the-shelf cell therapies intended for UK, EU, US markets.
• Partnership targets initial programs in recessive dystrophic epidermolysis bullosa, oncology candidates such as CORDStrom-TRAIL, inflammatory and degenerative diseases including osteoarthritis and systemic lupus erythematosus.
• Deal includes traceability and quality provisions aligned with GMP and Human Tissue Authority standards to support regulatory pathways with FDA, EMA, MHRA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief on May 05, 2026, and is solely responsible for the information contained therein.